

CITATION REPORT

List of articles citing

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

DOI: 10.1186/s13561-019-0257-3
Health Economics Review, 2019, 9, 40.

Source: <https://exaly.com/paper-pdf/74365876/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	New thiazolopyrimidine as anticancer agents: Synthesis, biological evaluation, DNA binding, molecular modeling and ADMET study. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 127611	2.9	4
4	Pegaspargase preferred option in acute lymphoblastic leukaemia. <i>PharmacoEconomics & Outcomes News</i> , 2020 , 844, 30-30	0.1	
3	Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. <i>Frontiers in Pediatrics</i> , 10,	3.4	1
2	Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece. 2022 , 42, 999-1008		0
1	Experience with Generic Pegylated L-asparaginase in Children with Acute Lymphoblastic Leukemia from a Tertiary Care Oncology Center in South India.		0